We are live on ! Find out more
RETA

Reata Pharmaceuticals, Inc. Class A Common Stock
RETA

Delisted

RETA was delisted on the 25th of September, 2023.

Back to rankings

93 hedge funds and large institutions have $427M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 40 increasing their positions, 16 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 16

102% more call options, than puts

Call options by funds: $2.05M | Put options by funds: $1.02M

82% more capital invested

Capital invested by funds: $235M → $427M (+$192M)

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

8% more funds holding

Funds holding: 86 → 93 (+7)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
93
Holders Change
+7
Holders Change %
+8.14%
% of All Funds
2.13%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
20
Increased
40
Reduced
16
Closed
13
Calls
$2.05M
Puts
$1.02M
Net Calls
+$1.03M
Net Calls Change
+$913K

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$11.4M
2
BlackRock
BlackRock
New York
+$9.5M
3
DM
Deerfield Management
New York
+$6.69M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$6.06M
5
State Street
State Street
Massachusetts
+$3.98M

Top Sellers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
-$6.54M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.9M
3
UBS AM
UBS AM
Illinois
-$3.59M
4
LCM
Laurion Capital Management
New York
-$3.31M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$3.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$2.47M +$647K +21,244 +43%
AIC
27
AWM Investment Company
New York
$2.45M +$152K +5,000 +8%
OWD
28
Osborn Williams & Donohoe
Ohio
$2.44M – – –
Bank of New York Mellon
29
Bank of New York Mellon
New York
$2.29M +$502K +16,473 +34%
Morgan Stanley
30
Morgan Stanley
New York
$1.86M +$168K +5,504 +12%
GH
31
GAM Holding
Switzerland
$1.61M +$1.4M +46,100 New
SCM
32
Sio Capital Management
New York
$1.53M +$1.34M +43,842 New
CC
33
Capital Counsel
New York
$1.44M +$765K +25,118 +157%
PAWC
34
P.A.W. Capital
Connecticut
$1.4M -$609K -20,000 -33%
MWVC
35
Morgens Waterfall Vintiadis & Co
New York
$1.4M +$1.22M +40,000 New
Deutsche Bank
36
Deutsche Bank
Germany
$1.33M +$599K +19,678 +108%
UBS Group
37
UBS Group
Switzerland
$1.23M +$460K +15,112 +76%
TCIM
38
TIAA CREF Investment Management
New York
$1.06M +$189K +6,195 +26%
Goldman Sachs
39
Goldman Sachs
New York
$1.06M +$24.9K +818 +3%
Fayez Sarofim & Co
40
Fayez Sarofim & Co
Texas
$1.05M +$918K +30,129 New
Stifel Financial
41
Stifel Financial
Missouri
$997K +$18.8K +616 +2%
TA
42
Teachers Advisors
New York
$951K +$194K +6,356 +30%
CM
43
Crestline Management
Texas
$925K -$1.9M -62,236 -70%
Swiss National Bank
44
Swiss National Bank
Switzerland
$906K +$183K +6,000 +30%
UC
45
Unterberg Capital
New York
$874K – – –
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$851K +$208K +6,845 +39%
EGM
47
Engineers Gate Manager
New York
$841K +$732K +24,043 New
WC
48
Woodstock Corp
Massachusetts
$830K +$121K +3,978 +20%
First Manhattan
49
First Manhattan
New York
$807K +$704K +23,100 New
CS
50
Credit Suisse
Switzerland
$806K +$143K +4,708 +26%
1
2
3 4 5

RETA Hedge Fund Activity: Q2 2018 in Review

93 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q2 2018, worth a combined $427M — up 82% from $235M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new RETA positions and 13 closed out — a net gain of 7 holders — while 40 added to existing stakes and 16 trimmed.

The largest buyer was Ameriprise, adding an estimated $11.4M. The largest seller was Prosight Management, cutting an estimated $6.54M.

  • 93 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q2 2018, up from 86 in Q1 2018.
  • Funds reported $427M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q2 2018, up 82% quarter-over-quarter.
  • 20 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q2 2018 and 13 closed out, a net change of +7 holders.
  • The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q2 2018 was Ameriprise, an estimated $11.4M added.
  • The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q2 2018 was Prosight Management, an estimated $6.54M sold.

Based on aggregated 13F filings for Q2 2018.